Table 4 Treatment patterns: patients with no flares and with flares occurring during follow-up of 12 months (N = 19,369)
From: Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population
Ever during 12 months | No flares | Total (any flare) | 1 flare | 2 flares | 3 flares | |||||
|---|---|---|---|---|---|---|---|---|---|---|
after index date | (n = 19,369) | (n = 15,893) | (n = 2,790) | (n = 686) | ||||||
n | % | n | % | n | % | n | % | n | % | |
NSAIDS | 58325 | 36.9% | 15730 | 81.2% | 12821 | 80.7% | 2338 | 83.8% | 571 | 83.2% |
selective | 10110 | 6.4% | 2345 | 12.1% | 1795 | 11.3% | 430 | 15.4% | 120 | 17.5% |
nonselective | 53750 | 34.0% | 15076 | 77.8% | 12278 | 77.3% | 2245 | 80.5% | 553 | 80.6% |
Colchicine | 19353 | 12.2% | 10333 | 53.3% | 7929 | 49.9% | 1855 | 66.5% | 549 | 80.0% |
Corticosteroids | 28379 | 17.9% | 8845 | 45.7% | 6695 | 42.1% | 1666 | 59.7% | 484 | 70.6% |
Probenecid | 1781 | 1.1% | 729 | 3.8% | 503 | 3.2% | 174 | 6.2% | 52 | 7.6% |
Allopurinol | 44110 | 27.9% | 12434 | 64.2% | 9662 | 60.8% | 2170 | 77.8% | 602 | 87.8% |
No treatment | 69241 | 43.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |